Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
INBX - Inhibrx, Inc.
Market Cap 883.22M P/E - EPS this Y 2,093.00% Ern Qtrly Grth -
Income 1.72B Forward P/E -4.78 EPS next Y -110.80% 50D Avg Chg -18.00%
Sales 1.69M PEG - EPS past 5Y - 200D Avg Chg -19.00%
Dividend N/A Price/Book 58.36 EPS next 5Y - 52W High Chg -42.00%
Recommedations 3.00 Quick Ratio 5.85 Shares Outstanding 14.48M 52W Low Chg 61.00%
Insider Own 23.55% ROA - Shares Float 7.68M Beta -
Inst Own 67.42% ROE - Shares Shorted/Prior 677.72K/752.85K Price 20.25
Gross Margin - Profit Margin 101,974.22% Avg. Volume 355,133 Target Price 11.00
Oper. Margin -160,898.00% Earnings Date Aug 13 Volume 482,838 Change -1.32%
Healthcare | Biotechnology | United States
About Inhibrx, Inc.

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

Inhibrx, Inc. News
11/17/24 The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares
11/14/24 Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
11/04/24 Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
09/13/24 Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX)
08/13/24 Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
05/24/24 Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
05/10/24 Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
05/08/24 Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
02/28/24 Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
02/28/24 Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
09:26 AM Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
01/24/24 Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
01/24/24 Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
01/23/24 Inhibrx Soared 176% Over Two Months — Now, Sanofi Is Buying It
01/23/24 Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
01/23/24 Sanofi to buy Inhibrx in deal worth up to $2.2B
01/23/24 France's Sanofi boosts rare disease business with about $2.2 billion Inhibrx deal
01/23/24 UPDATE 3-France's Sanofi boosts rare disease business with about $2.2 bln Inhibrx deal
01/23/24 Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Aug 28 Buy 19.35 511,627 9,899,982 511,627 08/30/23
Eckelman Brendan P. Chief Scientific Off.. Chief Scientific Officer Feb 01 Sell 25.27 40,000 1,010,800 2,075,553 02/02/23
Lappe Mark Chief Executive Offi.. Chief Executive Officer Jan 23 Sell 25.73 26,000 668,980 2,486,252 01/24/23
Kayyem Jon Faiz Director Director Jan 23 Sell 25.2631 9,500 239,999 3,224,301 01/23/23
Eckelman Brendan P. Chief Scientific Off.. Chief Scientific Officer Jan 03 Sell 23.99 40,000 959,600 2,115,553 01/04/23
Eckelman Brendan P. Chief Scientific Off.. Chief Scientific Officer Nov 01 Sell 33.62 40,000 1,344,800 2,195,553 11/02/22
Lappe Mark Chief Executive Offi.. Chief Executive Officer Oct 17 Sell 30.22 26,000 785,720 2,564,252 10/18/22
Eckelman Brendan P. Chief Scientific Off.. Chief Scientific Officer Sep 06 Sell 15.26 40,000 610,400 2,435,553 09/07/22
Eckelman Brendan P. Chief Scientific Off.. Chief Scientific Officer Jul 07 Sell 17.17 40,000 686,800 2,515,553 07/08/22